Can I Take Quercetin with Rapamycin (Sirolimus)?

Why This Interaction Matters

Rapamycin (sirolimus) has one of the narrowest therapeutic indices of any oral medication. A small increase in blood concentration can shift the drug from a well-tolerated longevity or immunosuppressive dose into a range that causes mouth ulcers, cytopenias, and hyperlipidemia. Quercetin, a flavonoid sold as an antioxidant and antihistamine supplement, interferes with the two primary clearance routes for sirolimus: cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) [1].

The Narrow Therapeutic Window

For transplant patients, sirolimus trough targets typically range from 4 to 12 ng/mL, and toxicity risk climbs steeply above 15 ng/mL [2]. Even in off-label longevity protocols where clinicians use lower, intermittent doses (often 1 to 6 mg once weekly), an unexpected doubling of drug exposure could mimic daily immunosuppressive dosing. That distinction is not trivial. The difference between weekly pulse dosing and daily suppressive dosing defines whether sirolimus acts as a partial mTOR modulator or a full immunosuppressant [3].

Who Is Most at Risk

Patients taking sirolimus daily for transplant rejection prevention face the greatest absolute risk. But the growing population using rapamycin off-label for longevity often self-prescribes quercetin from the same "anti-aging stack" retailers, creating an under-monitored overlap. Neither group should combine these agents without lab verification of trough levels.

How Quercetin Affects Rapamycin Metabolism

Sirolimus is absorbed in the small intestine, where it encounters two gatekeepers before reaching systemic circulation: CYP3A4 enzymes embedded in enterocytes and P-gp efflux pumps on the apical membrane. The liver then performs a second pass of CYP3A4 metabolism. Together, these pathways account for more than 90% of sirolimus clearance [1][2].

CYP3A4 Inhibition

In vitro studies show quercetin inhibits CYP3A4 with IC50 values ranging from 1.1 µM in recombinant enzyme systems to 11.4 µM in human liver microsomes [4]. A 500 mg oral dose of quercetin can produce peak plasma concentrations of roughly 1 to 2 µM, but gut-lumen concentrations after an oral dose are substantially higher, potentially exceeding the IC50 for intestinal CYP3A4 [5]. This means even moderate supplement doses may meaningfully reduce first-pass metabolism of sirolimus in the gut wall.

P-glycoprotein Inhibition

Quercetin also inhibits P-glycoprotein, the efflux transporter that pumps sirolimus back into the intestinal lumen before it can be absorbed. A 2004 study by Choi et al. Demonstrated that quercetin (15 mg/kg) increased the oral bioavailability of cyclosporine (another calcineurin inhibitor substrate of CYP3A4 and P-gp) by 64% in rats [6]. Sirolimus shares these transport pathways. While direct human pharmacokinetic trials combining quercetin with sirolimus have not been published as of May 2026, the mechanistic overlap is well-characterized enough that the Natural Medicines Comprehensive Database rates this interaction as "moderate" severity [7].

Net Effect on Drug Levels

The combined inhibition of CYP3A4 and P-gp creates a dual hit: more drug gets absorbed (P-gp block) and less drug gets metabolized on first pass (CYP3A4 block). The result is higher peak concentrations and a larger area under the curve (AUC). For a drug with a 62-hour half-life, elevated AUC translates into days of supratherapeutic exposure from a single dose interaction [2].

Pharmacokinetic vs. Pharmacodynamic Considerations

This interaction is primarily pharmacokinetic. Quercetin raises sirolimus levels by slowing its clearance rather than by amplifying the drug's action at the mTOR complex directly.

Is There a Pharmacodynamic Layer?

Some preclinical research suggests quercetin itself has mild mTOR-modulating properties. A 2015 study by Wang et al. Found quercetin suppressed mTORC1 signaling in hepatocellular carcinoma cell lines at concentrations of 40 to 80 µM [8]. Those concentrations are far above what oral supplementation achieves in plasma (typically <3 µM), so a clinically meaningful pharmacodynamic combination is unlikely at standard supplement doses. The pharmacokinetic interaction is the dominant concern.

The Antihistamine Angle

Quercetin is marketed heavily as a natural antihistamine, stabilizing mast cells and reducing histamine release. This effect does not interact with sirolimus pharmacology in a clinically significant way. Sirolimus does not modulate histamine pathways, so the antihistamine properties of quercetin are pharmacodynamically neutral with respect to rapamycin [5].

Dose-Separation Strategies

If a patient and prescriber decide the benefits of both agents justify co-use, timing matters. Separating doses by at least 4 to 6 hours may reduce the magnitude of gut-level CYP3A4 and P-gp inhibition, though it will not eliminate hepatic CYP3A4 inhibition entirely.

Practical Timing Protocol

For patients on weekly rapamycin protocols, taking quercetin on non-rapamycin days offers the widest margin. A patient who takes rapamycin every Monday morning could take quercetin Tuesday through Sunday and skip it on Monday. This approach exploits the fact that quercetin's CYP3A4 inhibition is largely reversible and concentration-dependent, with an elimination half-life of roughly 11 to 28 hours [5].

When Separation Is Not Enough

For transplant patients on daily sirolimus, dose separation alone provides minimal protection because quercetin's inhibitory effect on hepatic CYP3A4 persists between doses. In this population, the safer approach is to avoid quercetin entirely or substitute a flavonoid with a weaker CYP3A4 profile, such as luteolin, after confirming with the transplant team [4].

Monitoring Requirements

Any patient combining quercetin with sirolimus needs tighter lab surveillance than standard protocols provide.

Sirolimus Trough Levels

Draw a sirolimus trough level before adding quercetin to establish a baseline. Repeat the trough 5 to 7 days after starting quercetin (allowing roughly two sirolimus half-lives for a new steady state). If the trough rises by more than 20% from baseline, the interaction is clinically meaningful, and the prescriber should consider dose adjustment or quercetin discontinuation [2][9].

Additional Labs

Sirolimus toxicity manifests in predictable patterns. Monitor these markers at baseline and 4 weeks after adding quercetin:

• CBC with differential: sirolimus-induced cytopenias (thrombocytopenia, leukopenia) are dose-dependent. A platelet count dropping below 100,000/µL warrants immediate trough reassessment [9].
• Fasting lipid panel: sirolimus raises LDL cholesterol and triglycerides in a dose-responsive manner. A fasting triglyceride level exceeding 500 mg/dL increases pancreatitis risk [2].
• Hepatic function panel: both quercetin (at high doses) and sirolimus undergo hepatic processing. AST or ALT elevation above 3x the upper limit of normal should prompt reevaluation [9].
• Serum creatinine and eGFR: while sirolimus is less nephrotoxic than calcineurin inhibitors, supratherapeutic levels can impair renal function, particularly in patients with pre-existing kidney disease [2].

Signs of Toxicity to Report

Patients should know the early warning signs of sirolimus overexposure: persistent mouth sores (aphthous ulcers), unusual bruising or bleeding, unexplained fatigue, and new-onset acne or skin rash. These symptoms should prompt an urgent trough level.

What If You Are Already Taking Both?

Do not stop either agent abruptly without medical guidance. Discontinuing sirolimus suddenly in transplant patients risks acute rejection. Stopping quercetin without adjusting sirolimus could cause a drop in drug levels if the prescriber has already dose-reduced to account for the interaction.

Step-by-Step Approach

1. Contact your prescribing clinician before making changes.
2. Get a sirolimus trough level drawn at your next lab visit or sooner if you have symptoms.
3. If the trough is within target range and you are asymptomatic, your current regimen may be safe to continue under monitoring.
4. If the trough is elevated above target, your clinician will likely recommend stopping quercetin first and rechecking levels in 5 to 7 days.
5. Document your quercetin brand, dose, and schedule so the clinician can assess the interaction magnitude accurately.

Evidence Gaps and What the Literature Says

Direct clinical trial data on simultaneous quercetin and sirolimus administration in humans does not exist as of May 2026. The interaction is inferred from three evidence streams.

In Vitro Enzyme Studies

Multiple groups have confirmed quercetin inhibits CYP3A4 in human liver microsomes. Kimura et al. (2010) reported an IC50 of 1.1 µM using recombinant CYP3A4, while Rastogi and Jana (2016) found 11.4 µM in pooled human liver microsomes [4][10]. The discrepancy reflects differences in enzyme source and substrate, but both values fall within the range achievable by oral supplementation.

Animal Pharmacokinetic Studies

Choi et al. (2004) demonstrated that quercetin increased cyclosporine bioavailability by 64% in a rat model, with the effect attributed to combined CYP3A4 and P-gp inhibition [6]. Because sirolimus shares these clearance pathways, pharmacologists extrapolate a similar magnitude of interaction.

Case Reports and Clinical Extrapolation

No published case reports describe quercetin-sirolimus toxicity specifically, but case reports of sirolimus toxicity from other CYP3A4 inhibitors (grapefruit juice, ketoconazole, erythromycin) consistently show 2- to 5-fold increases in trough levels [11]. The FDA prescribing information for sirolimus lists CYP3A4 inhibitors as contraindicated or requiring dose reduction [9].

Dr. Matt Kaeberlein, a researcher who has published extensively on rapamycin in aging biology, noted in a 2022 commentary that "the biggest risk with off-label rapamycin is not the drug itself but the unmonitored polypharmacy that often accompanies it" [3]. This observation applies directly to the quercetin combination scenario.

Other Supplements That Interact with Rapamycin via CYP3A4

Quercetin is not the only supplement that inhibits CYP3A4. Patients taking rapamycin should be aware of the broader field.

High-Risk CYP3A4 Inhibitors

• Grapefruit juice: well-documented to increase sirolimus levels 2- to 3.5-fold. The FDA label explicitly warns against co-use [9].
• Curcumin (turmeric extract): inhibits CYP3A4 with an IC50 of approximately 7 µM. Supplement doses of 1,000 to 2,000 mg may produce gut concentrations above this threshold [4].
• Berberine: inhibits both CYP3A4 and P-gp. A 2020 study found berberine increased cyclosporine AUC by 88% in healthy volunteers [12].

Lower-Risk Alternatives

Patients seeking antioxidant or anti-inflammatory support while on rapamycin might consider supplements with minimal CYP3A4 activity: vitamin C, vitamin E (alpha-tocopherol), or omega-3 fatty acids. These do not share the enzymatic inhibition profile of flavonoid polyphenols [4].

The Bottom Line for Longevity Protocol Users

The off-label longevity community often pairs rapamycin with quercetin under the assumption that both target aging pathways. The biological rationale has some preclinical support: quercetin is a senolytic agent in combination with dasatinib, and rapamycin modulates mTOR. But the pharmacokinetic interaction creates a real safety signal that preclinical mechanistic logic does not resolve.

Weekly rapamycin users who insist on quercetin should take quercetin only on days they do not take rapamycin, check a sirolimus trough level within the first two weeks of co-use, and repeat trough monitoring quarterly. Transplant patients should avoid quercetin supplements entirely unless the transplant team explicitly approves co-use with enhanced monitoring.

A sirolimus trough level costs between $25 and $75 at most reference laboratories and takes 2 to 3 business days to result. That investment is small compared to the clinical cost of undetected supratherapeutic exposure over weeks or months [2][9].